Porcine bone marrow stromal cell differentiation on heparin-adsorbed poly(e-caprolactone)-tricalcium phosphate-collagen scaffolds

Acta Biomaterialia

Volumn 5, Issue 9, 2009, Pages 3305-3315

  Chum, Zhi Zhen ^a   Woodruff, Maria A ^b   Cool, Simon M ^c,d   Hutmacher, Dietmar W ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d INSTITUTE OF MEDICAL BIOLOGY   (Singapore)

Author keywords

Cell differentiation; Heparin; PCL Collagen; Scaffold

Indexed keywords

BONE; CELLS; CYTOLOGY; METABOLISM; POLYSACCHARIDES; SCAFFOLDS (BIOLOGY); SUBSTRATES; TRANSMISSION CONTROL PROTOCOL;

3D SCAFFOLDS; BONE MARROW STROMAL CELLS; CELL DIFFERENTIATION; COLLAGEN TYPE I; OSTEOGENIC; PCL-COLLAGEN; POLY(E-CAPROLACTONE); PORCINE BONES; PRECURSOR CELLS; TRI-CALCIUM PHOSPHATES;

COLLAGEN;

ALIZARIN RED S; CALCIUM PHOSPHATE; COLLAGEN TYPE 1; HEPARIN; MOLECULAR SCAFFOLD; OIL; POLYCAPROLACTONE;

ADIPOGENESIS; ADSORPTION KINETICS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; BONE TISSUE; CELL CULTURE; CELL DIFFERENTIATION; CELL LINEAGE; CELL METABOLISM; CELL PROLIFERATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HEMATOPOIETIC STEM CELL; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; STROMA CELL; SWINE; THREE DIMENSIONAL IMAGING; TISSUE ENGINEERING;

SUS;

EID: 70349847474     PISSN: 17427061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.actbio.2009.05.015     Document Type: Article

References (37)

1. Blair H., Sun L., and Kohanski R.A. Balanced regulation of proliferation, growth, differentiation, and degradation in skeletal cells. Ann N Y Acad Sci 1116 1 (2007) 165-173
2. Cool S.M., and Nurcombe V. The osteoblast-heparan sulfate axis: control of the bone cell lineage. Int J Biochem Cell Biol 37 9 (2005) 1739-1745
3. Cool S.M., and Nurcombe V. Heparan sulfate regulation of progenitor cell fate. J Cell Biochem 99 4 (2006) 1040-1051
4. Kilcoyne M., and Joshi L. Carbohydrates in therapeutics. Cardiovasc Hematol Agents Med Chem 5 3 (2007) 186-197
5. Kock H.J., and Handschin A.E. Osteoblast growth inhibition by unfractionated heparin and by low molecular weight heparins: an in vitro investigation. Clin Appl Thromb Hemost 8 3 (2002) 251-255
6. Zhang F., McLellan J.S., Ayala A.M., Leahy D.J., and Linhardt R.J. Kinetic and structural studies on interactions between heparin or heparan sulfate and proteins of the hedgehog signaling pathway. Biochemistry 46 13 (2007) 3933-3941
7. Mazanec D.J., and Grisanti J.M. Drug-induced osteoporosis. Cleve Clin J Med 56 3 (1989) 297-303
8. Squires J.W., and Pinch L.W. Heparin-induced spinal fractures. Jama 241 22 (1979) 2417-2418
9. Wawrzynska L., Tomkowski W.Z., Przedlacki J., Hajduk B., and Torbicki A. Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol Haemost Thromb 33 2 (2003) 64-67
10. Rajgopal R., Butcher M., Weitz J.I., and Shaughnessy S.G. Heparin synergistically enhances interleukin-11 signaling through up-regulation of the MAPK pathway. J Biol Chem 281 30 (2006) 20780-20787
11. Hausser H.J., and Brenner R.E. Low doses and high doses of heparin have different effects on osteoblast-like Saos-2 cells in vitro. J Cell Biochem 91 5 (2004) 1062-1073
12. Caplan A.I. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol (2007)
13. Zou X., Li H., Baatrup A., Lind M., and Bunger C. Engineering of bone tissue with porcine bone marrow stem cells in three-dimensional trabecular metal: in vitro and in vivo studies. APMIS Suppl 109 (2003) 127-132
14. Ringe J., Kaps C., Schmitt B., Buscher K., Bartel J., Smolian H., et al. Porcine mesenchymal stem cells. Induction of distinct mesenchymal cell lineages. Cell Tissue Res 307 3 (2002) 321-327
15. Hsu S.H., Yen H.J., Tseng C.S., Cheng C.S., and Tsai C.L. Evaluation of the growth of chondrocytes and osteoblasts seeded into precision scaffolds fabricated by fused deposition manufacturing. J Biomed Mater Res B Appl Biomater 80 2 (2007) 519-527
16. Hutmacher D.W., and Woodruff M.A. Fabrication and characterisation of scaffolds via solid free form fabrication techniques. Handbook of fabrication and processing of biomaterials vol. 1 (2007), CRC Press/Taylor and Francis Group, Boca Raton, FL
17. Zhou Y., Chen F., Ho S.T., Woodruff M.A., Lim T.M., and Hutmacher D.W. Combined marrow stromal cell-sheet techniques and high-strength biodegradable composite scaffolds for engineered functional bone grafts. Biomaterials 28 5 (2007) 814-824
18. Osmond R.I., Kett W.C., Skett S.E., and Coombe D.R. Protein-heparin interactions measured by BIAcore 2000 are affected by the method of heparin immobilization. Anal Biochem 310 2 (2002) 199-207
19. Mizuno M., Fujisawa R., and Kuboki Y. Type I collagen-induced osteoblastic differentiation of bone-marrow cells mediated by collagen-alpha2beta1 integrin interaction. J Cell Physiol 184 2 (2000) 207-213
20. Guimond S.E., and Turnbull J.E. Fibroblast growth factor receptor signalling is dictated by specific heparan sulphate saccharides. Curr Biol 9 22 (1999) 1343-1346
21. Turnbull J., Powell A., and Guimond S. Heparan sulfate: decoding a dynamic multifunctional cell regulator. Trends Cell Biol 11 2 (2001) 75-82
22. Ibrahimi O.A., Eliseenkova A.V., Plotnikov A.N., Yu K., Ornitz D.M., and Mohammadi M. Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome. Proc Natl Acad Sci U S A 98 13 (2001) 7182-7187
23. Itoh N., and Ornitz D.M. Evolution of the Fgf and Fgfr gene families. Trends Genet 20 11 (2004) 563-569
24. Naski M.C., and Ornitz D.M. FGF signaling in skeletal development. Front Biosci 3 (1998) d781-d794
25. Ornitz D.M. FGF signaling in the developing endochondral skeleton. Cytokine Growth Factor Rev 16 2 (2005) 205-213
26. Perlyn C.A., Morriss-Kay G., Darvann T., Tenenbaum M., and Ornitz D.M. A model for the pharmacological treatment of crouzon syndrome. Neurosurgery 59 1 (2006) 210-215 discussion 210-5
27. Ornitz D.M. FGFs, heparan sulfate and FGFRs: complex interactions essential for development. Bioessays 22 2 (2000) 108-112
28. Gospodarowicz D., and Cheng J. Heparin protects basic and acidic FGF from inactivation. J Cell Physiol 128 3 (1986) 475-484
29. Moscatelli D. Basic fibroblast growth factor (bFGF) dissociates rapidly from heparan sulfates but slowly from receptors. Implications for mechanisms of bFGF release from pericellular matrix. J Biol Chem 267 36 (1992) 25803-25809
30. Rapraeger A.C., Krufka A., and Olwin B.B. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 252 5013 (1991) 1705-1708
31. Yayon A., Klagsbrun M., Esko J.D., Leder P., and Ornitz D.M. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64 4 (1991) 841-848
32. Irie A., Habuchi H., Kimata K., and Sanai Y. Heparan sulfate is required for bone morphogenetic protein-7 signaling. Biochem Biophys Res Commun 308 4 (2003) 858-865
33. Aviezer D., and Yayon A. Heparin-dependent binding and autophosphorylation of epidermal growth factor (EGF) receptor by heparin-binding EGF-like growth factor but not by EGF. Proc Natl Acad Sci U S A 91 25 (1994) 12173-12177
34. Reichsman F., Smith L., and Cumberledge S. Glycosaminoglycans can modulate extracellular localization of the wingless protein and promote signal transduction. J Cell Biol 135 3 (1996) 819-827
35. Zioncheck T.F., Richardson L., Liu J., Chang L., King K.L., Bennett G.L., et al. Sulfated oligosaccharides promote hepatocyte growth factor association and govern its mitogenic activity. J Biol Chem 270 28 (1995) 16871-16878
36. Guimond S., Turner K., Kita M., Ford-Perriss M., and Turnbull J. Dynamic biosynthesis of heparan sulphate sequences in developing mouse brain: a potential regulatory mechanism during development. Biochem Soc Trans 29 Pt 2 (2001) 177-181
37. Luong-Van E., Grondahl L., Nurcombe V., and Cool S. In vitro biocompatibility and bioactivity of microencapsulated heparan sulfate. Biomaterials 28 12 (2007) 2127-2136